10:49 AM EDT, 06/27/2025 (MT Newswires) -- Biogen (BIIB) said a higher dose regimen of nusinersen led to measurable improvements in motor function among individuals with spinal muscular atrophy, including those previously stabilized on the standard 12 mg dose.

Trial data showed most participants who received a 50 milligram loading dose and two 28 mg maintenance doses experienced functional gains, the company said Friday in a statement. These patients had been on the 12 mg regimen for almost four years before transitioning to the higher dose.

Over an eight-year period, 92% of children treated with nusinersen achieved the ability to walk independently, the company said.

The safety profile of the higher dose was consistent with earlier trial results, the company said.

Regulatory applications for the new dosing regimen are under review in the U.S., Europe, Japan and other markets.

Price: 127.60, Change: +0.68, Percent Change: +0.54